In this study, we found that gradual changes across PET−/plasma−, PET−/plasma+, and PET+/plasma+ regarding tau burden, brain volume, cognitive function, cognitive decline, and PRS could support plasma biomarkers as early biomarker of amyloidopathy prior to amyloid PET. This evidence concerns the gene MAPT and Mental deterioration.